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Abstract
Background: X11-family proteins, including X11, X11-like (X11L) and X11-like 2 (X11L2), bind to the cytoplasmic
domain of amyloid b-protein precursor (APP) and regulate APP metabolism. Both X11 and X11L are expressed
specifically in brain, while X11L2 is expressed ubiquitously. X11L is predominantly expressed in excitatory neurons,
in contrast to X11, which is strongly expressed in inhibitory neurons. In vivo gene-knockout studies targeting X11,
X11L, or both, and studies of X11 or X11L transgenic mice have reported that X11-family proteins suppress the
amyloidogenic processing of endogenous mouse APP and ectopic human APP with one exception: knockout of
X11, X11L or X11L2 has been found to suppress amyloidogenic metabolism in transgenic mice overexpressing the
human Swedish mutant APP (APPswe) and the mutant human PS1, which lacks exon 9 (PS1dE9). Therefore, the
data on X11-family protein function in transgenic human APP metabolism in vivo are inconsistent.
Results: To confirm the interaction of X11L with human APP ectopically expressed in mouse brain, we examined
the amyloidogenic metabolism of human APP in two lines of human APP transgenic mice generated to also lack
X11L. In agreement with previous reports from our lab and others, we found that the amyloidogenic metabolism
of human APP increased in the absence of X11L.
Conclusion: X11L appears to aid in the suppression of amyloidogenic processing of human APP in brain in vivo,a s
has been demonstrated by previous studies using several human APP transgenic lines with various genetic
backgrounds. X11L appears to regulate human APP in a manner similar to that seen in endogenous mouse APP
metabolism.
Background
X11 proteins (X11s) comprise a family of three adaptor
proteins in mammals: X11 (X11/X11a/Mint1), X11-like
(X11L/X11b/Mint2) and X11-like 2 (X11L2/X11g/
Mint3) [1]. These molecules are evolutionally conserved
in D. melanogaster [2,3] and C. elegans [4]. In mammals,
X11 and X11L are expressed predominantly in neurons,
while X11L2 is expressed ubiquitously [reviewed in ref.
[5]]. X11s associate with the cytoplasmic domain of
amyloid b-protein precursor (APP) and suppress APP
metabolism, including amyloid b-protein (Ab) genera-
tion [1,6,7], which is widely believed to be the major
cause of Alzheimer’s disease (AD) pathogenesis [8]. APP
is subjected to alternative cleavages by a combination of
a- and g-secretases or b- and g-secretases. Primary clea-
vage of APP by a-secretase is amyloidolytic and gener-
ates a C-terminal fragment, CTFa, which includes the
C-terminal half of the Ab sequence, whereas cleavage by
b-secretase is amyloidogenic and generates CTFb, which
includes an intact Ab sequence. Both CTFa and CTFb
are further cleaved by g-secretase in the lipid bilayer,
resulting in the secretion of the amyloidolytic p3 frag-
ment from CTFa and the neurotoxic Ab from CTFb [9].
The association of X11s with APP is mediated by
interaction between the phosphotyrosine interaction
domain (PTB) of X11s and the 681-GYENPTY-687
m o t i fo fA P P .T h i sa s s o c i ation has been shown to
greatly suppress the amyloidogenic metabolism of APP
in the brain in vivo. Specifically, the production of amy-
loidogenic CTFb, but not amyloidolytic CTFa, derived
from endogenous mouse APP was found to be
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be increased, in the brains of X11-knockout, X11L-
knockout, and X11 plus X11L double-gene knockout
mice [10-12]. Recent evidence indicates that the major-
ity of both b- and g-secretases are located in cholesterol-
and sphingolipid-rich detergent-resistant membrane
domains (DRM domains or lipid rafts) as active forms
[13,14]. DRMs in the brains of mice lacking X11 and
X 1 1 La r er i c hi nm a t u r eA P P( N- and O-glycosylated
form), the substrate to secretases, and the amyloidogenic
metabolite CTFb [11]. These observations suggest that
X11 and X11L function to form a complex with APP
that then remains outside of the DRMs. In this way,
they regulate amyloidogenic cleavage of APP through
suppression. This suppressive inhibition of human APP
amyloidogenic metabolism by X11 and X11L was also
confirmed in the brains of X11- or X11L-Tg mice
expressing human Swedish mutant APP (APPswe/
Tg2576) [15,16] (Table 1). On the other hand, a contro-
versial report analyzing human APP metabolism in the
brains of mice lacking X11s found that the amyloido-
genic metabolism of APPswe was suppressed in the
brains of mice lacking X11 proteins and constitutively
expressing the active PS1 mutant PS1dE9 [17] (Table 1).
In this study, we investigated whether the amyloidogenic
metabolism of human APP, as well as endogenous
mouse APP, is facilitated in murine brains lacking X11L.
We focused on X11L, rather than X11, because it is
more widely distributed and because it suppresses APP
metabolism more strongly [10,11]. Our data showed
increased amyloidogenic metabolism in two transgenic
mouse lines expressing relatively higher (APP23) and
lower (APP-ibl) levels of human APPswe in the absence
of X11L, indicating that X11L functions to suppress
APP amyloidogenic metabolism in brain in vivo.
Results
APP metabolism in APP23 mouse brain lacking X11L
The amyloidogenic metabolism of endogenous APP in
brain was facilitated in X11-, X11L-, and X11 plus
X11L- gene knockout mice, while a contrary result was
reported for exogenously expressed human APPswe in
X11s (X11, X11L or X11L2)- gene knockout mice [17].
X 1 1 L - g e n ek n o c k o u tm i c eh a v eb e e ns h o w nt oe x h i b i t
more strongly enhanced amyloidogenic metabolism of
endogenous APP as compared with X11-gene knockout
mice [10,11]. Thus, we reexamined the function of X11L
in the suppression of APP amyloidogenic metabolism
using X11L-gene knockout mice and human APPswe
transgenic mouse lines.
We first generated APP23 mice lacking X11L because
APP23 mice have been established as a transgenic line
expressing human APP751swe [18,19], and the expres-
sion level of APP in these mice is high enough to allow
Table 1 Effect of X11s in the generation of Ab in the brains of several transgenic and knock-out mouse lines
Reference
number in text
Authors & Journal X11 family genes APP and PS genes Examination of
brain Ab levels
Effect of X11s in the
generation of Ab
[10] Sano et al.,
J. Biol. Chem. (2006)
281, 37853-37860.
X11L, knock-out endogenous
mouse APP
mouse Ab40
mouse Ab42
suppressive
[11] Saito et al.,
J. Biol. Chem. (2008)
283, 35763-35771
X11, X11L, & X11/
X11L, knock-out
endogenous
mouse APP
mouse Ab40
mouse Ab42
suppressive
[15] Lee et al.,
J. Biol. Chem. (2003)
278, 47025-47029.
X11, transgenic human APPswe
transgenic (Tg2576)
human Ab40
human Ab42
suppressive
[16] Lee et al.,
J. Biol. Chem. (2004)
279, 49099-49104.
X11L, transgenic human APPswe
transgenic (Tg2576)
human Ab40
human Ab42
suppressive
[17] Ho et al.,
J. Neurosci. (2008)
28, 14392-14400.
X11, X11L or X11L2,
knock-out
human APPswe/PS1dE9
double-transgenic
human Ab40
human Ab42
facilitative
[23] Saluja et al.,
Neurobiol. Dis. (2009)
36, 162-168.
X11, heterozygous
knock-out
human APPswe/PS1dE9
double-transgenic
human Ab40
human Ab42
suppressive
[24] Mitchell et al.,
Hum. Mol. Genet. (2009)
18, 4492-4500.
X11L, transgenic human APPswe
transgenic
(Tg2576)
human Ab40
human Ab42
suppressive
Present results Kondo et al.,
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X11L, knock-out human APPswe
transgenic
(APP23),
human APPswe
transgenic
(APP-ibl)
human Ab40
human Ab42
suppressive
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Page 2 of 11the observation of amyloid plaques in mice at around 10
months. The overproduction of Ab is still milder in
APP23 than in APPswe-Tg/PS1dE9-Tg, another human
APP transgenic mouse model that constitutively over-
produces Ab to grow amyloid plaques at younger ages
and has been used in previous analyses [17,20]. APP23
may be the better model for precise evaluation of the
regulatory role of X11L. We first examined human
APPswe expression in the APP23 X11L knockout
(APP23/X11L-Ko) mouse brain. The brain regions used
included the cerebral cortex, hippocampus and olfactory
bulb of wild-type, APP23 and APP23/X11L-Ko mice (5-
6 months old). Membrane (P100) and cytoplasmic
(S100) fractions were prepared and analyzed for human
APP, human-plus-mouse APP, X11L and flotillin-1 (as a
marker for membrane protein) by immunoblotting with
respective antibodies (Fig. 1A). We confirmed that the
human APP level did not change significantly in APP23
mice lacking X11L (Fig. 1A, first rows; Fig.1 B ,left).
Using the same samples, we examined the level of amy-
loidogenic fragment (CTFb/C99) derived from human
APP by immunoblotting with anti-human, Ab-specific
antibody (Fig. 1A, third rows). Our previous results
indicated that CTFb (C99) derived from endogenous
mouse APP increased in X11L-deficient mouse brains
[11]. In agreement with these data, we found that the
human CTFb (C99) from APPswe also increased signifi-
cantly in the brains of APP23/X11L-Ko mice when com-
pared with APP23 mice (Fig. 1A, third rows; Fig.1 B ,
right).
We further examined secreted human Ab and human
sAPP, large extracellular N-terminal domain truncated
at the a-site (sAPPa)a n d / o rb-site (sAPPb), levels in
t h es a m es a m p l e s( F i g s .2a n d3 ) .H u m a nA b40 and
Ab42 significantly increased in APP23/X11L-Ko mice
(Fig. 2). Since the difference between Ab40 and Ab42 is
dependent on alternative intramembrane g-cleavage, we
investigated the increase in primary b-site cleavage by
detecting human sAPPbswe (Fig. 3A, third rows). The
sAPPbswe, derived from human APPswe, was detected
by immunoblotting with anti-sAPPbs w es p e c i f i ca n t i -
body, which showed a significant increase in sAPPbswe
in APP23/X11L-Ko mice (Fig. 3B, right). The total
levels of human sAPP and sAPPa were not significantly
altered (Fig. 3A, first and second rows; Fig.3 B ,left
and middle). These analyses indicate that a lack of
X11L facilitates the primary amyloidogenic processing of
human APP at the b-site, but not at the a-site, as has
been previously shown for the processing of endogenous
mouse APP in X11L-Ko mouse brains [11].
If amyloidogenic processing of human APP were to
progress in the brains of APP23/X11L-Ko mice, amyloid
plaques would be expected to appear at younger ages
than is seen in APP23 mice. It has been well established
that amyloid plaque formation appears in ~10 month
APP23 mice. Thus, we examined the formation of amy-
loid plaques in both 5, 9 and 12 month mice of APP23
and APP23/X11L-Ko. At five months, amyloid plaques
appeared in neither APP23, nor APP23/X11L mice
(Additional file 1, Fig. S1), but at nine months, amyloid
plaques appeared in both APP23 and APP23/X11L-Ko
mice (Additional file 1, Fig. S2). Brain slices of mice (12
months old) were immunostained with anti-human Ab
antibody, the plaque numbers increased remarkably in
APP23/X11L-Ko when compared to APP23 (Fig. 4A).
The numbers of amyloid plaques in the two lines,
APP23 and APP23/X11L-Ko (12 months old), were
quantified in 18 serial sections from six individuals (Fig.
4B). The sections, including the cerebral cortex, the hip-
pocampus and the entorhinal cortex, were analyzed for
t h ep l a q u en u m b e r s .T h ea v e r a g en u m b e ro fa m y l o i d
plaques was 48.5 per section in APP23/X11L-Ko mice,
but only 18.8 per section in APP23 mice, indicating that
plaque numbers significantly increase in brains lacking
X11L.
Taken together with previous observations that the
numbers of amyloid plaques were decreased in the
brains of X11- or X11L-tg mice expressing human
APPswe [15,16], the present observation indicates that
X11L plays an important role in the suppression of the
amyloidogenic and pathogenic metabolism of human
APP, as well as the observation of facilitated amyloido-
genic metabolism of endogenous APP in X11-, X11L-,
and X11 plus X11L- knockout mice [10,11].
APP metabolism in APP-ibl mouse brain lacking X11L
The analysis described above was also performed with
another APP transgenic mouse line, APP-ibl, which was
generated using human APP695swe. In contrast to
APP23, which expressed relatively higher levels of
human APP751swe, APP-ibl expressed levels of human
APP 1.2-1.4 times those of endogenous mouse APP (Fig.
5A, second rows; Fig.5 B ,right). The human APP level
was similar between APP-ibl and APP-ibl/X11L-Ko
mice brain (Fig. 5A, first rows; Fig.5 B ,left), as was
observed in APP23 and APP23/X11L-Ko (Fig. 1). The
level of the amyloidogenic fragment of human APP,
CTFb (C99), increased significantly in APP-ibl/X11L-Ko
(5-6 months old) when compared to the same age of
APP-ibl mice (Fig. 6Aand 6B). We also examined the
levels of another CTFb (C89) and CTFa (C83), along
with CTFb (C99), by immunoblotting with pan-APP
CTF antibody, which detects both human and mouse
CTFs (Fig. 6Cand 6D). Both C99 and C89 CTFb levels
increased significantly in APP-ibl/X11L-Ko mouse
brains, while the levels of CTFa (C83) were the same
regardless of X11L expression. The enhanced amyloido-
genic metabolism of APP was further confirmed by
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in APP-ibl/X11L-Ko as compared with APP-ibl mice for
both Ab40 and Ab42 at 5-6 months of age (Fig. 7). In
contrast to the APP23 mice, at 12 months of age, the
APP-ibl mice had not generated any amyloid plaques
(data not shown). This is probably because the levels of
Ab40 and Ab42 are much lower than those in APP23
mice (1/15-1/20 the levels of APP23 mice) (compare
Fig. 2 to Fig. 7).
In summary, we used two human APP transgenic
mouse lines lacking the X11L gene and found that X11L
functions in the suppression of amyloidogenic metabo-
lism of human APP, as it does for mouse endogenous
APP, in brain in vivo.
Figure 1 Expression of APP and generation of primary amyloidogenic fragment CTFb in APP23 mice in the presence or absence of
X11L.( A) Expression of human APP751swe and detection of human CTFb (C99) in APP23 mouse brain samples in the presence or absence of
X11L and in wild-type mice. Membrane (P100 for APP, CTFb and flotillin-1) and cytoplasmic (S100 for X11L) fractions of brain regions composed
of the cerebral cortex, hippocampus and olfactory bulb from wild-type (WT), APP23 and APP23/X11L-Ko mice (5-6 months old) were analyzed for
the expression of transgenic human APP751swe (anti-APP 10D1 antibody), total APP (human APP751swe combined with mouse endogenous
APP695, anti-APP/c 8717 antibody), human APP C99 (CTFb, anti-human Ab 82E1 antibody), X11L and flotilin-1 by immunoblotting. For human
APP, the upper band indicates mature APP751swe (mAPP) and the lower band indicates immature APP751swe (imAPP). For mouse APP (see
lanes of WT), the upper two bands are mAPP695 and lower band is imAPP695. To identify CTF species with or without phosphorylation at
Thr668, the lysates were subjected to dephosphorylation prior to detection as described in Materials and Methods (for identification of APP and
CTF molecules, reviewed in Suzuki and Nakaya [12]). (B) The densities of human APP751swe (left) and C99 (right) bands were standardized to
the density of flotillin-1, which was compared with the ratios for APP23 mice that were assigned a reference value of 1.0 (values represent the
means ± S.E.). The data were analyzed by Student’s t test (n = 10; *, p < 0.05).
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The qualitative and quantitative alteration of Ab genera-
tion is a major cause of AD pathogenesis. Familial Alz-
heimer’s disease (FAD)-linked presenilin-1 mutations
increase the longer, pathogenic Ab42 species. APP locus
duplication also induces an increase in Ab generation.
Both of these cases, one showing qualitative and one
showing quantitative alteration of Ab generation, induce
early-onset AD [8,21,22]. Because the pathological pro-
gression of sporadic AD (SAD) is similar to that of
FAD, the regulation of Ab generation (in terms of both
quality and quantity) is also important in SAD patho-
genesis, regardless of the absence of known causative
genetic mutations.
The regulation of APP metabolism is closely related to
intracellular protein sorting, in which many regulatory
molecules associate directly or indirectly with APP
[9,12]. The X11 family proteins X11, X11L and X11L2
directly associate with APP through their PTB domains.
This protein interaction is thought to regulate the meta-
bolism and intracellular trafficking of APP. In cells
expressing APP together with X11, X11L, or X11L2,
APP metabolism is remarkably suppressed, with a con-
sequential decrease in Ab generation [1,6,7]. However,
in vitro studies have not been able to fully characterize
the molecular function of X11L in APP metabolism in
brain. To resolve this issue, several lines of transgenic
and knockout mice for X11 genes were produced and
used to examine APP metabolism in brain in vivo,
including Ab generation and/or amyloid plaque forma-
tion. X11 and X11L transgenic mice expressing human
APPswe show decreased levels of cerebral Ab and
reductions in Ab plaques in comparison with mice
expressing APPswe alone [15,16]. Furthermore, amyloi-
dogenic metabolism of endogenous mouse APP has
been shown to be facilitated in the brains of X11-,
X11L- and X11 plus X11L- gene knockout mice [10,11],
indicating that X11s function physiologically to suppress
the amyloidogenic metabolism of APP. These results
have been confirmed by similar studies [23,24], but also
conflict with a report that X11s (X11, X11L or X11L2)-
gene Ko mice overexpressing APPswe and PS1dE9
decreased Ab generation at younger ages [17].
We consider that the contrary results may be depen-
dent on the presence or absence of mutations in the
PS1 gene because PS1 is known to regulate intracellular
protein trafficking [25]. Transgenic mice with APPswe
and PS1dE9 genes (APPswe/PS1dE9-tg) generate larger
amounts of Ab without intracellular regulation of APP
metabolism and trafficking. APPsw/PS1dE9 mice are
suitable as an AD model showing AD pathology [20],
but may not be suitable for analysis of the regulation of
intracellular APP metabolism. Therefore, in this study,
we used two lines of X11L-Ko mice expressing human
Figure 2 Human Ab levels in APP23 mouse brain samples in the presence or absence of X11L. Quantification of human Ab40 (left) and
Ab42 (right) in brain samples composed of the cerebral cortex, hippocampus and olfactory bulb from APP23 and APP23/X11L-Ko mice (5-6
months old) was performed by sELISA. Concentrations were normalized to tissue weight. The data were analyzed by Student’s t test. Statistical
significance is indicated with asterisks (n = 10; *, p < 0.05). The error bars are S.E.
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expresses APP751swe [19]. The other, APP-ibl, is an
X11L-Ko line expressing APP695swe in lower levels. We
used X11L-Ko mice alone to examine the effects on the
metabolism of the transgenic APP molecule because
X11L-Ko mice showed a stronger increase in amyloido-
genic metabolism of endogenous APP than X11-Ko.
The level of this effect was similar to that in X11/X11L
double-Ko mice [11]. We confirmed that, in both mice
expressing higher (APP23) and lower (APP-ibl) levels of
APPswe in the absence of X11L, amyloidogenic APP
metabolism increased. These results coincide well with
previous reports demonstrating that X11s function to
suppress [10,11,15,16,23,24], but not to enhance [17],
the amyloidogenic metabolism of APP (summarized in
Table 1).
Conclusions
In conclusion, X11L plays an important role in suppres-
sive regulation of APP amyloidogenic metabolism in
Figure 3 Human sAPP levels in APP23 mouse brain samples in the presence or absence of X11L. (A) Detection of total human sAPP,
sAPPa and sAPPbswe along with human APP, X11L and a-tubulin in APP23 mouse brain tissue in the presence or absence of X11L. Membrane
(P100 for APP) and cytoplasmic (S100 for sAPP, sAPPa, sAPPbswe, X11L and a-tubulin) fractions of brain regions composed of cerebral cortex,
hippocampus and olfactory bulb from wild-type (WT), APP23 and APP23/X11L-Ko mice (5-6 months old) were analyzed for total human sAPP
(sAPPa plus sAPPbswe by 10D1 antibody), human sAPPa (2B3 antibody), human sAPPbswe (6A1 antibody), human APP (10D1 antibody), X11L
and a-tubulin by immunoblotting. (B) The densities of total human sAPP (left), sAPPa (middle) and sAPPbswe (right) bands were standardized to
the density of a-tubulin, which was compared with the ratios for APP23 mice that were assigned a reference value of 1.0 (values represent the
means ± S.E.). The data were analyzed by Student’s t test (n = 10; **, p < 0.01).
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may provide useful targets in the development of drugs
to suppress the amyloidogenic metabolism of APP in
AD.
Materials and methods
Mice
The X11L-Ko mouse has been described [10]. The
human APP751swe-tg APP23 mouse was kindly sup-
p l i e df r o mN o v a r t i sP h a r m aI n c .[ 1 9 ] .T h eA P P - i b l
transgenic mouse was generated through transduction
of human APP695swe cDNA driven by the PDGFb pro-
motor. The DNA was injected into fertilized eggs from
a BDF strain mouse, and the founder was selected by
DNA hybridization and then subjected to back-cross
with the C57BL/6 strain. APP23/X11L-Ko and APP-ibl/
X11L-Ko mice were generated by mating with X11L-Ko
mice generated from a C57BL/6 background [10], and
heterozygous human APPswe transgenic [tg+/-, X11L-/-
] and [tg+/-, X11L+/+] mutant mice were used for the
study.
Antibodies
Mouse monoclonal antibodies to human Ab 82E1
(IBL) and 6E10 (Signet COVANCE), human APP 10D1
(IBL), sAPPa 2B3(IBL), sAPPbswe 6A1 (IBL), actin
(Chemicon), flotillin-1 (BD Transduction Laboratories),
a-tubulin (Zymed and Santa Cruz Biotechnologies),
Figure 4 Quantification of amyloid plaques in APP23 mouse brain in the presence or absence of X11L. Immunostaining of coronal
sections of the brain region including the cerebral cortex and hippocampus of APP23 (Fig. 4A, upper panels) and APP23/X11L-Ko mice (Fig. 4B,
lower panels) at 12 months of age is shown. The brain sections were stained with anti-Ab 82E1 antibody to detect human Ab. Stains indicate
amyloid plaque. Bar, 300 μm. The data were analyzed by Student’s t test (n = 4 serial sections × 6 individuals respectively; **, p < 0.01). The error
bars are S.E.
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purchased. Monoclonal anti-Ab 2D1 antibodies were
generated as described in [26]. Rabbit polyclonal anti-
bodies to human Ab (IBL #18584) and 4G8 (Signet
COVANCE), and the APP cytoplasmic domain (Sigma
#8717) were purchased.
Brain lysates, fractionation and immunoblotting
Cerebral cortex, hippocampus and olfactory bulb tissue
samples from each hemisphere were homogenized in
eight volumes of buffer containing 10 mM Tris-HCl
(pH 7.8), 1% (w/v) SDS, 4 M urea, complete protease
inhibitor cocktail (Roche-diagnosis), and 1 μM pepstatin
on ice with 20 strokes of a Downce homogenizer,
sonicated twice for 10 sec, and centrifuged at 15,000 × g
for 15 min at 4°C. The supernatant was used for immu-
noblotting to detect APP, APP CTFs and X11L. The
membrane (P100) and cytosolic (S100) fractions were
prepared from mouse brain hemisphere samples, includ-
ing the cerebral cortex, hippocampus and olfactory bulb.
The P100 fraction was solubilized as described [11].
T h i sP 1 0 0w a su s e dt od e t e c tA P Pa n dA P PC T F s ,a n d
the S100 was used to detect sAPP in immunoblot analy-
sis. To identify each of the CTFs (C99, C89 and C83)
and their respective phosphorylated forms (pC99, pC89
and pC83), samples were subjected to dephosphoryla-
tion with l protein phosphatase as described [27] prior
to immunoblotting.
Figure 5 Expression of APP in APP-ibl mouse brain in the presence or absence of X11L.( A) Expression of human APP695swe and mouse
endogenous APP695. Brain regions composed of the cerebral cortex, hippocampus and olfactory bulb from wild-type (WT), APP-ibl and APP-ibl/
X11L-Ko mice (4 months old) were homogenized in 10 mM Tris-HCl [pH 7.9] containing 1% (w/v) SDS, 4 M urea, complete protease inhibitor
cocktail (Roche Diagnostics), and 1 μM pepstatin. The lysates were analyzed by immunoblotting with anti-human APP (10D1), anti-APP (8717),
anti-X11L and anti-a-tubulin antibodies. (B) The densities of human APP695swe (left) and human plus mouse APP (right) bands were
standardized to the density of a-tubulin, which was compared with the ratios for APP-ibl mice (left) or wild-type mice (right), which were
assigned a reference value of 1.0 (values represent means ± S.E.). The data were analyzed by Student’s t test (n = 3).
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Ab quantification was performed based on the proce-
dure described previously [10]. In brief, cerebral cortex,
hippocampus and olfactory bulb samples from each
hemisphere were homogenized in four volumes of Tris-
buffered saline (20 mM Tris-HCl [pH 7.6], 137 mM
NaCl) with 30 strokes of a Downce homogenizer and
centrifuged at 200, 000 × g for 20 min at 4°C. The pre-
cipitate was further homogenized in nine volumes of
TBS with 30 strokes and centrifuged at 100, 000 × g for
20 min at 4°C. One volume of 6 M guanidine chloride
in TBS was then added to the precipitate, sonicated for
10 sec twice, and allowed to stand for 1 h at room tem-
perature. The samples were then centrifuged at 130,000
× g for 20 min at 4°C. The supernatant was assayed
with sandwich enzyme-linked immunosorbent assay
(ELISA) kits (IBL 27714 for human Ab40 and IBL
27712 for human Ab42) following dilution with PBS
containing 1% (w/v) of BSA and 0.05% (v/v) of Tween
20 as follows: 24-fold for Ab40; 12-fold for Ab42 of
APP-ibl mice; 500-fold for Ab40; and 100-fold for Ab42
of APP23 mice.
Immunohistochemistry
Frozen mouse brain tissue sections (25-μmt h i c k )w e r e
immunostained by either (i) incubation for 1 h in PBS
containing 5% (v/v) normal horse serum with mouse
monoclonal antibodies, or (ii) incubation for 1 h in PBS
containing 5% (v/v) normal goat serum with rabbit poly-
clonal antibodies for blocking prior to overnight
Figure 6 Generation of primary amyloidogenic fragment CTFb in APP-ibl mice in the presence or absence of X11L.( A) Generation of
human CTFb in APP-ibl mice in the presence or absence of X11L. Brain regions composed of the cerebral cortex, hippocampus and olfactory
bulb from APP-ibl and APP-ibl/X11L-Ko mice (4 months old) were homogenized in 10 mM Tris-HCl [pH 7.9] containing 1% (w/v) SDS, 4 M urea,
complete protease inhibitor cocktail (Roche Diagnostics), and 1 μM pepstatin. The lysates were dephosphorylated as described [11,27] and
analyzed by immunoblotting with anti-human Ab (82E1) and anti-a-tubulin antibodies. (B) The density of human CTFb band was standardized
to the density of a-tubulin, which was compared with the ratios for APP-ibl mice that were assigned a reference value of 1.0 (values represent
the means ± S.E.). The data were analyzed by Student’s t test (n = 10; **, p < 0.01). (C) Generation of CTFa and CTFb in APP-ibl mice in the
presence or absence of X11L. Brain lysates of the cerebral cortex, hippocampus and olfactory bulb from wild-type (WT), APP-ibl and APP-ibl/
X11L-Ko mice (4 months old) were dephosphorylated and analyzed by immunoblotting with anti-APP/c 8717 and anti-a-tubulin antibodies. (D)
The densities of C99 (CTFb), C89 (CTFb) and C83 (CTFa) bands were standardized to the density of a-tubulin, which was compared with the
ratios for APP-ibl mice that were assigned a reference value of 1.0 (values represent means ± S.E.). The data were analyzed by Student’s t test
(n = 10; **, p < 0.01).
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Page 9 of 11incubation with primary antibody. For Ab staining, tis-
sue sections were incubated in PBS containing 0.3% (v/
v) H2O2 for 30 min and washed in PBS three times. The
sections were then incubated in PBS containing 70% (w/
v) formic acid for 1 min prior to blocking. After washing
the sections with PBS three times for 10 min, the sec-
tions were incubated with horse anti-mouse IgG or goat
anti-rabbit IgG antibodies conjugated with biotin (Vec-
tor Laboratories), followed by ABC complex. Peroxidase
activity was revealed using diaminobenzidine (DAB) as
the chromogen. The sections were viewed using a BZ-
9000 microscope (KEYENCE, Osaka, Japan).
Additional material
Additional file 1: Supplemental Figures. Supplemental Figures S1 and
S2
Abbreviations
Ab: b-amyloid; APP: Alzheimer’s b-amyloid precursor protein; APPswe; APP
carrying Swedish type mutation; sELISA: sandwich enzyme-linked
immunosorbent assay; mAPP: mature APP; BACE: b-site cleaving enzyme; PS:
presenilin; CTFa: the carboxyl-terminal fragment of APP cleaved at the a-
site; CTFb: the carboxyl-terminal fragment of APP cleaved at the b-site; sAPP:
large extracellular N-terminal domain truncated at the a-site (sAPPa) and/or
the b-site (sAPPb); DRM: detergent resistant membrane; X11s: X11 proteins
(X11, X11L plus X11L2); X11L: X11-like.
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